MedTrace Logo

Specialist Recommendation on FBC (Familial Breast Cancer) Chemoprevention Prescribing

NCT04058418 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-03-24

No results posted yet for this study

Summary

Some women are more likely to get breast cancer as it runs in their family, they are at risk of familial breast cancer. There are medications, called chemoprevention, which may lower their risk of developing breast cancer by a third. However chemoprevention can also cause serious side effects, like womb cancer and blood clots. This makes decision to start them difficult. Researchers found that not all women who can have these medications are on them.

The investigators want to ask familial breast cancer specialists whether they recommend general practitioners (GP) to prescribe chemoprevention, by sending them a short survey. These specialists look after women where breast cancer runs in the family. The specialists assess a women's chance of getting breast cancer and advice those with increased risk what can be done to prevent breast cancer.

The investigators will then look at whether specialist recommendation makes a difference to whether GPs prescribe chemoprevention medication. This will be done by linking the specialists' survey response to information on GP prescribing that the government regularly publishes. This may help the investigators understand why chemoprevention is not used as often as it potentially can be.

Conditions

  • Familial Breast Cancer

Interventions

OTHER

Survey Administration

Completion of a short survey.

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • University of Nottingham

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-22
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04058418 on ClinicalTrials.gov